Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a Read All » View HTML
Toggle Summary Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer San Diego, CA – Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to the Company’s Board of Directors, Read All » View HTML
Toggle Summary San Diego, CA  – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All » View HTML
Toggle Summary San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All » View HTML
Toggle Summary Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All » View HTML
Toggle Summary U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All » View HTML
Toggle Summary Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All » View HTML
Toggle Summary Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All » View HTML
Toggle Summary Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All » View HTML
Toggle Summary Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All » View HTML